On the heels of reporting its highest ever end-of-year results for revenue and profit, Almac Group, the global contract pharmaceutical development and manufacturing organization (CDMO), has unveiled a $250 million global capital investment plan to meet increased client demand over the next three years. Investment will take place in existing Almac locations in the UK, Europe, North America and Asia. 

“Almac is committed to re-investing all profits back into the business to ensure we are market leading for clients and offer the best possible work environment for our people,” said Alan Armstrong, CEO, Almac Group. “For our clients, we are investing $250 million on expansion to ensure we remain the global leaders in our industry and give them, and ultimately the patients across the globe who receive benefit from these therapeutics, the best possible offering from Almac.”

In their financial results for year ending September 30, 2021, Almac recorded a $79 million (8.6%) rise in revenue from $927 million in 2020 to $1.01 billion in 2021. Pre-tax profits were recorded at $111 million, up from $87 million (27.1% increase) for the same period the previous year. 

The report also detailed an increase in Almac’s average employee figures from 5,466 to 5,783 (5.8%) during the period of October 2020 to September 2021. Current employee numbers for the group now sits at over 6,500 and a current global recruitment drive will increase the total number to over 8,000 over the next three years.